Person: GÜRSOY, VİLDAN
Loading...
Email Address
Birth Date
4 results
Search Results
Now showing 1 - 4 of 4
Publication The evaluation of risk factors leading to early deaths in patients with acute promyelocytic leukemia: A retrospective study(Springer, 2022-02-21) Baysal, Mehmet; Gürsoy, Vildan; Hunutlu, Fazıl Çağrı; Erkan, Buket; Demirci, Ufuk; Baş, Volkan; Gülsaran, Sedanur Karaman; Pınar, İbrahim Ethem; Ersal, Tuba; Kırkızlar, Tuğcan Alp; Atlı, Emine Ikbal; Kırkızlar, Hakkı Onur; Ümit, Elif G.; Gürkan, Hakan; Özkocaman, Vildan; Özkalemkaş, Fahir; Demir, Ahmet Muzaffer; Ali, Rıdvan; GÜRSOY, VİLDAN; HUNUTLU, FAZIL ÇAĞRI; ERKAN ÖZMARASALI, BUKET; PINAR, İBRAHİM ETHEM; ERSAL, TUBA; ÖZKOCAMAN, VİLDAN; ÖZKALEMKAŞ, FAHİR; ALİ, RIDVAN; Tıp Fakültesi; İç Hastalıkları Ana Bilim Dalı; Hematoloji Bilim Dalı; 0000-0001-9907-1498 ; 0000-0002-4991-9830 ; CTT-7336-2022; KCK-7512-2024; CPN-8681-2022; JGM-6601-2023; AAJ-4354-2021; JIR-6730-2023; DLR-8474-2022; GXD-8209-2022Acute promyelocytic leukemia (APL) differs from other forms of acute myeloid leukemia (AML), including coagulopathy, hemorrhage, disseminated intravascular coagulation (DIC), and treatment success with all-trans retinoic acid (ATRA). Despite ATRA, early deaths (ED) are still common in APL. Here, we evaluated factors associated with ED and applicability of scoring systems used to diagnose DIC. Ninety-one APL patients (55 females, 36 males, and median age 40 years) were included. ED was defined as deaths attributable to any cause between day of diagnosis and following 30th day. DIC was assessed based on DIC scoring system released by the International Society of Thrombosis and Hemostasis (ISTH) and Chinese Diagnostic Scoring System (CDSS). Patients' median follow-up time was 49.2 months, and ED developed in 14 (15.4% of) cases. Patients succumbing to ED had higher levels of the Eastern Cooperative Oncology Group Performance Status (ECOG PS), lactate dehydrogenase (LDH), and ISTH DIC, and lower fibrinogen levels (p <0.05). In multivariate Cox regression analysis, age >55 and ECOG PS >= 2 rates were revealed to be associated with ED. Based on ISTH and CDSS scores, DIC was reported in 47.3 and 58.2% of the patients, respectively. Despite advances in APL, ED is still a major obstacle. Besides the prompt recognition and correction of coagulopathy, those at high ED risk are recommended to be detected rapidly. Implementation of local treatment plans and creating awareness should be achieved in hematological centers. Common utilization of ATRA and arsenic trioxide (ATO) may be beneficial to overcome ED and coagulopathy in APL patients.Publication Retrospective analysis of clinical efficacy of erlotinib in patients with non-small cell lung cancer(Derman Medical Publ, 2015-03-01) ÖZKAYA, GÜVEN; Ayyıldız, Aylin; Kanat, Özkan; DELİGÖNÜL, ADEM; Deligönül, Adem; Gürsoy, Vildan; GÜRSOY, VİLDAN; Tıp Fakültesi; Biyoistatistik Ana Bilim Dalı; 0000-0003-0297-846X; A-4421-2016Aim: In this study, we aimed to evaluate the efficacy and safety of erlotinib as second-, third-, and fourth-line treatment for Turkish patients with advanced non-small cell lung cancer (NSCLC). Material and Method: Thirty-nine patients with advanced, previously treated NSCLC who received 150 mg of erlotinib once daily orally until disease progression or intolerable toxicity were retrospectively analyzed. Results: We observed no complete response, partial responses were observed in 7 (17.9%) patients, and 16 (41 Ph) patients had stable disease. The median progression -free survival was 242 days (95% CI 51-224), and the median overall survival (OS) was 377 days (950/0 Cl 291462). The median 05 of females was significantly better than male patients (470 vs. 271 days, p=0.046). The treatment was generally well tolerated. The most common side effect was skin rash (4105). Discussion: Erlotinib was safe and effective in treating Turkish patients with advanced NSCLC who had been previously treated with the standard chemotherapy.Publication Efficacy of plerixafor plus g-csf in patients with multiple myeloma and lymphoma who have had mobilization failure with at least two regimens. a retrospective study(Springernature, 2022-11-01) Özkocaman, V.; ÖZKOCAMAN, VİLDAN; Pınar, İbrahim Ethem; PINAR, İBRAHİM ETHEM; Özkalemkas, Fahri; ÖZKALEMKAŞ, FAHİR; Ersal, Tuğba; ERSAL, TUBA; Buldu, Merve; BULDU, MERVE; Gürsoy,; GÜRSOY, VİLDAN; Tıp Fakültesi; 0000-0001-9907-1498; 0000-0002-0116-2082; JGM-6601-2023; M-1070-2014; JWP-2738-2024Publication Cd5 as a prognostic marker in patients with diffuse large B-cell lymphoma: A multicenter study(Springer, 2022-12-10) Demirci, Ufuk; Kırkızlar, Hakkı Onur; Ümit, Elif G.; Gürsoy, Vildan; Pınar, İbrahim Ethem; Özkalemkas, Fahir; Güven, Zeynep Tuğba; Kaynar, Leylagül; Karadağ, Fatma Keklik; Saydam, Güray; Ekinci, Ömer; Merter, Mustafa; Aras, Merih Reis; Albayrak, Murat; Guülsaran, Sedanur Karaman; Baş, Volkan; Aydın, Berrin Balık; Bekoz, Hüseyin Saffet; Can, Ferda; Dilek, Imdat; Mehtap, Özgür; Öztürk, Erman; Şmşek, Bengu Çobanoğlu; Yıldırım, Murat; Ayli, Meltem; Ataş, Unal; Salim, Ozan; Ayer, Mesut; Atesoglu, Elif Birtaş; Akay, Olga Meltem; Yüksel, Meltem Kurt; Paydas, Semra; Korkmaz, Selçuk; Puyan, Fulya Öz; Demir, Ahmet Muzaffer; PINAR, İBRAHİM ETHEM; ÖZKALEMKAŞ, FAHİR; GÜRSOY, VİLDAN; 0000-0001-6923-1470; 0000-0001-7523-8599; 0000-0001-9907-1498; 0000-0003-1600-9731; 0000-0002-2035-9462; 0000-0003-1977-0104; 0000-0003-0369-299X; 0000-0003-4642-3693; 0000-0003-4632-6850; IZQ-0529-2023; JGM-6601-2023; A-7077-2018; U-5707-2018; IAM-9057-2023; GYR-1246-2022; AAY-5233-2020; AAS-4929-2020; F-6991-2013; JWP-2738-2024; JUU-5382-2023; F-3132-2018; ABD-2313-2022; A-7804-2016; W-9594-2018Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) and comprises a heterogeneous group of disease. While classification of B-cell lymphomas has been evolving to include clonality in a specific manner, morphology, and immunohistochemistry remain the backbone. We aimed to evaluate the value of CD5 expression on disease characteristics as well as prognosis in patients with DLBCL. Data of 131 patients with DLBCL with CD5 positivity and as a comparison arm, data of 129 patients with DLBCL without CD5 positivity were evaluated. Mean age was 59 and 55.7% of the patients were male. Overall survival was 29.8 months. Poor prognostic factors including (high-LDH levels, B symptoms, low ECOG score, high R-IPI and NCCN-IPI score) were observed to be significantly related with CD5 positivity. Mean survival in CD5 positive patients were 29.8 months, which is significantly shorter than the general DLBCL survival worldwide. CD5 expression shall be evaluated in all samples of DLBCL patients due to its possible effects on outcomes.